ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MRTX Mirati Therapeutics Inc

58.70
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Mirati Therapeutics Inc NASDAQ:MRTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 58.70 58.90 58.70 0 01:00:00

Form 15-12G - Securities registration termination [Section 12(g)]

02/02/2024 9:05pm

Edgar (US Regulatory)



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 
FORM 15


 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
 
Commission File Number: 001-35921
 

MIRATI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)


3545 Cray Court,
San Diego, California 92121
Telephone: (858) 332-3410
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)



 Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
Rule 12g-4(a)(1)

Rule 12g-4(a)(2)

Rule 12h-3(b)(1)(i)

Rule 12h-3(b)(1)(ii)

Rule 15d-6

Rule 15d-22(b)

 
Approximate number of holders of record as of the certification or notice date: One holder
 


Pursuant to the requirements of the Securities Exchange Act of 1934, Mirati Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: February 2, 2024
Mirati Therapeutics, Inc.




By:
/s/ Kimberly Jablonski

Name:
Kimberly Jablonski

Title:
Vice President and Secretary




1 Year Mirati Therapeutics Chart

1 Year Mirati Therapeutics Chart

1 Month Mirati Therapeutics Chart

1 Month Mirati Therapeutics Chart

Your Recent History

Delayed Upgrade Clock